Comparative Pharmacology
Head-to-head clinical analysis: IHEEZO versus OHTUVAYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IHEEZO versus OHTUVAYRE.
IHEEZO vs OHTUVAYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iheezo (phentolamine ophthalmic solution) is an alpha-adrenergic antagonist that inhibits sympathetic tone to the iris dilator muscle, preventing mydriasis and facilitating pupil constriction during ocular surgery.
OHTUVAYRE is an antisense oligonucleotide that binds to the survival motor neuron 2 (SMN2) pre-mRNA, altering splicing to increase production of full-length survival motor neuron (SMN) protein.
1 drop in the affected eye(s) 3 times daily as needed for relief of ocular discomfort. For optimal use, administer at least 10 minutes apart from other ophthalmic medications.
OHTUVAYRE (vadadustat) is administered orally at a starting dose of 300 mg once daily. The dose may be titrated based on hemoglobin response in increments of 150 mg up to a maximum of 600 mg once daily.
None Documented
None Documented
The terminal elimination half-life of proparacaine is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, resulting in a very short duration of systemic exposure.
Terminal elimination half-life is approximately 20 hours (range 15-25 h), supporting once-daily dosing.
IHEEZO (proparacaine) is predominantly metabolized by plasma esterases; less than 5% is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily renal excretion as unchanged drug: 70-80% in urine, with approximately 20% in feces via biliary elimination.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid